Researchers from Zjengzhou University reported on the discovery and preclinical characterization of a novel PROTAC agent aimed at overcoming paclitaxel (Taxol) resistance in non-small-cell lung cancer treatment.
Eli Lilly & Co. has selected FHD-909, a first-in-class oral BRM-selective inhibitor, for clinical development from its 2021 collaboration with Foghorn Therapeutics Inc. Lilly plans to file an IND for FHD-909 in the second quarter of this year. The primary target patient population is BRG1-mutated non-small-cell lung cancer.
Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties.
Researchers at Kanazawa University, Japan, have reported a mixed-glial culture on/in soft substrate (MGS) platform to investigate cancer-glia interactions in vitro. Using this model, they showed that astrocytes favored brain metastasis by promoting metabotropic glutamate mGlu1 receptor (mGluR1) expression in cancer cells and stabilizing EGFR. Eishu Hirata, an associate professor at the Cancer Research Institute, Division of Tumor Cell Biology and Bioimaging at Kanazawa University, and his team
published their work on Feb. 2, 2024, in Developmental Cell.
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Oncology company Arrivent Biopharma Inc.’s stock (NASDAQ:AVBP) shot up 11% on Jan. 26, its first day of trading, with its upsized IPO pricing 9.72 million shares at $18 each, raising gross proceeds of $175 million.
CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
What had been viewed as a major catalyst for Gilead Sciences Inc. going into 2024 turned into a disappointment on the stock market, as antibody-drug conjugate Trodelvy (sacituzumab govitecan) failed to meet the overall survival primary endpoint in the phase III Evoke-01 study in previously treated metastatic non-small-cell lung cancer (NSCLC).
